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Abstract: 
 
Three bioactive compounds were isolated from an organic extract of an ascomycete fungus of the 
order Chaetothyriales (MSX 47445) using bioactivity-directed fractionation as part of a search 
for anticancer leads from filamentous fungi. Of these, two were benzoquinones [betulinan A (1) 
and betulinan C (3)], and the third was a terphenyl compound, BTH-II0204-207:A (2). The 
structures were elucidated using a set of spectroscopic and spectrometric techniques; the 
structure of the new compound (3) was confirmed via single-crystal X-ray diffraction. 
Compounds 1–3 were evaluated for cytotoxicity against a human cancer cell panel, for 
antimicrobial activity against Staphylococcus aureus and Candida albicans, and for 
phosphodiesterase (PDE4B2) inhibitory activities. The putative binding mode of 1–3 with 
PDE4B2 was examined using a validated docking protocol, and the binding and enzyme 
inhibitory activities were correlated. 
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Article: 
 
Historically, natural products have played an important role in drug discovery. Of the 1355 
newly approved drugs worldwide during the time period of 1981–2010, ∼50% can be traced to, 
or were inspired by, natural products.(1) Moreover, of the 13 natural product-derived drugs that 
were approved in the U.S. between 2005 and 2007, five were the first members of new 
classes,(2) and in 2010, fingolimod, an analogue of the fungal metabolite myriocin, was 
approved as the first oral drug to reduce multiple sclerosis relapses.(3) In July of 2012, 
carfilzomib, an analogue of the natural product epoxomicin, which was isolated originally from 
an Actinomycete,(4) was approved to treat patients with multiple myeloma.(5) In short, natural 
products remain an invaluable source for novel bioactive leads. 
 
As part of a multidisciplinary project to identify structurally diverse anticancer leads,(6, 7) the 
Mycosynthetix library, representing over 55 000 accessions of filamentous fungi, is being 
examined systematically.(8-12) Fungi represent an underexplored source for bioactive secondary 
metabolites. In 1991, the number of fungi was estimated as 1.5 million species,(13) while current 
estimates suggest more than 5.1 million species.(14) Regardless, fewer than 100 000 species 
have been characterized taxonomically,(14) with likely a smaller percentage studied for bioactive 
secondary metabolites, and only a portion of these have been evaluated for anticancer activity. 
 
An organic fraction of the filamentous fungus MSX 47445,(9) which was isolated from highly 
decomposed woody debris from a tropical forest in 1990, displayed modest but equipotent 
cytotoxic activity against a panel of three cancer cell lines: MCF-7, H460, and SF268 (∼75% 
inhibition of cell growth when tested at 20 μg/mL). Hence, this fungus was selected for further 
study, and three compounds, two benzoquinones (1 and 3) and one terphenyl compound (2), 
were isolated and characterized. All three compounds were evaluated for cytotoxicity against a 
human cancer cell panel, for antimicrobial activity against Staphylococcus aureus and Candida 
albicans, and for their phosphodiesterase (PDE4B2) inhibitory activities; the results with the 
latter were the most encouraging and led to docking studies. 
 
Result and Discussion 
 
A solid-phase culture of MSX 47445 was extracted with 1:1 CHCl3–MeOH and partitioned with 
organic solvents to yield an orange-red extract, which was purified using flash chromatography 
to yield seven fractions. Of these, fraction 2 was the most cytotoxic against three cancer cell 
lines, and it was subjected to further purifications using preparative and semipreparative HPLC 
to yield three compounds (1–3) with >97% purity as measured by UPLC (Supporting 
Information Figure S1). 
 
Compound 1 (30.2 mg) was obtained as an orange powder. The molecular formula was 
determined as C20H16O4 by HRESIMS. The NMR data, in conjunction with HRMS data and 
UV maxima of 194, 238, and 320 nm, identified 1 as the known compound betulinan A, first 
described by Lee et al.(15) in 1996 from the fungus Lenzites betulina. 
 
 
Compound 2 (12.1 mg) was obtained as a pale yellow powder. HRESIMS data suggested a 
molecular formula of C19H16O3. The compound showed distinctive UV maxima at 202, 259, 
and 315 nm. The NMR data were in agreement with those reported for BTH-II0204-207:A, a 
terphenyl compound first reported in 2011 by Beggins et al.(16) from the pathogenic bacterium 
Burkholderia pseudomallei. 
 
Compound 3 (6.2 mg) was obtained as an orange powder. The molecular formula was 
determined as C19H14O3 via HRESIMS, establishing an index of hydrogen deficiency of 13. 
The UV maxima (198, 235, and 331 nm) and NMR data suggested structural similarity with 
compound 1, although a key difference was the loss of structural symmetry. Relative to 1, 
compound 3 also lacked one methoxy moiety, as supported by a 30 amu difference in the HRMS 
data. 1H NMR data (Table 1) revealed the presence of 10 aromatic protons (δH 7.45–7.52 for H-
2′ to H-6′ and δH 7.33–7.42 for H-2″ to H-6″), suggesting two monosubstituted benzene rings, 
one olefinic proton (δH 6.88, H-6), and one methoxy group (δH 3.80, 3-OCH3). The 13C NMR 
data revealed the presence of 19 carbons, consistent with the molecular formula and indicative of 
two carbonyls, which were assigned as quinone carbons (δC 187.4 and 183.3, for C-1 and C-4, 
respectively), four olefinic carbons (δC 132.7, 155.4, 144.5, and 133.0, for C-2, C-3, C-5, and C-
6, respectively), and 10 aromatic carbons (δC 130.7, 128.2, 129.0, 128.2, 130.7, 129.4, 128.8, 
130.3, 128.8, and 129.4, for C-2′, C-3′, C-4′, C-5′, C-6′, C-2″, C-3″, C4″, C-5″, and C-6″, 
respectively). Thus far, the spectroscopic data accounted for 12 of the 13 degrees of unsaturation, 
and hence, the 13th degree completed the quinone ring. COSY data identified two spin systems, 
which corresponded to the aromatic protons of the two phenyl rings. An HMBC correlation was 
observed from 3-OCH3 to C-3, indicating the connectivity of the methoxy group. HMBC 
correlations from H-6 to C-4, C-2, and C-1′ were observed. NOESY correlations were observed 
from the olefinic proton H-6 to the equivalent C-2′/C-6′ and from the 3-OCH3 to the equivalent 
C-2″/C-6″ (Figure 1b). The last structure elucidation hurdle was to verify whether the central 
ring was an ortho or para quinone, but the spectroscopic data were inconclusive, since the 
observed HMBC and NOESY correlations for the H-3 and the 3-OCH3 were equally valid for 
either substitution pattern. What increased the dilemma of the substitution pattern were 
contradictory NMR data that were published by two different research groups for a synthetic(17) 
and a natural(18) compound with the same molecular formula (compound 4). Our NMR data 
were in agreement with those reported by Singh and co-workers, except for one carbon where the 
13C NMR data differed by about 12 ppm.(18) Sawayama et al.(17) reported the synthesis of 4, 
where clear differences were observed between the NMR data of synthetic and natural 4, and 
they stated that reexamination of the structure of natural 4 was “underway by Dr. S. B. Singh”. 
However, since this reexamination has not been reported yet, compound 3 was crystallized from 
ethyl acetate at room temperature to give monoclinic crystals, and single-crystal X-ray 
diffraction established the structure of 3 with the carbonyl carbons para to each other (Figure 1a). 
To be consistent with the literature, the trivial name betulinan C was ascribed to 3. 
 
 
 
 
Figure 1. (a) X-ray crystallographic structure with 50% probability ellipsoids. (b) Key HMBC 
and NOESY correlations of 3. 
 
Compounds structurally related to 1–3 have been identified as phosphosdiesterase (PDE) 
inhibitors. Terferol (5), which was isolated from Streptomyces showdoensis SANK 65080, 
possessed inhibitory activity against cyclic adenosine 3′,5′-monophosphate phosphodiesterase 
(cAMP-PDE) and cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE).(19) 
The concentrations of 5 required for 50% inhibition of cAMP-PDE and cGMP-PDE were 0.82 
and 0.96 μM, respectively.(19) Moreover, Biggins et al.(16) evaluated two terferol-related 
compounds, BTH-II0204-207:A (2) and BTH-II0204-207:C, for PDE inhibition activity against 
11 PDE families. The latter was inactive, while 2 showed activity against PDE11 as well as four 
out of the five PDE4s that were examined. PDE4 is an essential regulator of the secondary 
messenger cAMP in numerous cell types, and the reduction in cAMP degradation by several 
inhibitors, such as rolipram, piclamilast, roflumilast, cilomilast, and tetomilast, has suggested a 
broad range of clinical applications for the treatment of asthma and chronic obstructive 
pulmonary disease (COPD),(20, 21) some types of brain tumors,(22, 23) and other inflammatory 
diseases.(24) In 2011, roflumilast (Daliresp) was approved by the U.S. FDA as the first selective 
PDE4 inhibitor to reduce COPD exacerbations.(25) Moreover, abnormal regulation of cAMP 
and/or cGMP metabolism upon altered expression and activity of PDE isoforms has been 
implicated in the pathogenesis of various types of cancer, including prostate cancer, colon 
cancer, hematological malignancies, melanoma, and brain tumors.(26, 27) On the basis of these 
reports, the effects of 1–3 on the activity of recombinant human PDE4B2(28) were evaluated; 
PDE4B is the predominant isoform present in human monocytes and neutrophils and is involved 
mainly in inflammation.(29) Of these, 3 was the most potent, with an IC50 value of 17 μM, 
followed by compounds 2 and 1, with IC50 values of 31 and 44 μM, respectively (Figure 2; 
Table 2). 
 
 
Figure 2. Plots of the effect of compounds 1–3 and rolipram (positive control) on PDE4B2 
activity. Substrate conc = 100 nM (cAMP). 
 
 
 
Molecular docking and other computational approaches are being used increasingly to explore 
the ligand-binding interactions of PDE4 inhibitors.(30-33) As such, compounds 1–3 were docked 
into the crystal structure of human PDE4B using Glide Extra Precision.(34, 35) The docking 
protocol was verified by testing its ability to reproduce the experimental binding mode of 
cocrystallized rolipram (Supporting Information Figure S4). To this end, rolipram bound to the 
crystal structure was removed from the binding pocket and docked back into the cofactor binding 
site; the root-mean-square deviation between the predicted conformation and the observed X-ray 
crystallographic data was 1.1 Å, indicating the capability of the docking protocol to reproduce 
the binding mode of rolipram (Supporting Information Figure S4). Compounds 1–3 were docked 
into the cAMP binding site of PDE4B. The docking scores calculated with Glide correlated with 
the biological activity (Table 2); compound 3 displayed the highest activity (IC50 value of 17 
μM) and also the top-ranked docking score (−8.732 kcal/mol). In contrast, compound 1 had the 
lowest activity (IC50 value of 44 μM) and showed the lowest docking score (−8.071 kcal/mol). 
Finally, the pyrrolidinone rolipram was included, not only for the docking protocol validation, 
but also as a positive control in the enzymatic assay; rolipram was top ranked in both docking 
score and in vitro activity. 
 
Compounds 1–3 and rolipram displayed a similar binding mode (Figures 3 and S5). The two 
predicted hydrogen bonds between the free amino group of Gln443 and the cyclopentyloxy and 
methoxyphenyl groups of rolipram were in agreement with the observations derived from the 
crystallographic structure of PDE4B in complex with rolipram. As shown, Glide found a similar 
hydrogen bond with Gln443 and the carboxyl group for the most active compound, 3 (Figure 3c 
and d); favorable π interactions with Phe446 in the binding pocket were also observed. 
Compounds 1 and 2 did not show hydrogen bonds with Gln433, but similar π interactions were 
predicted (Figures 3a, b and S5). Taken together, these observations suggested that the binging 
modes predicted with Glide for compounds 1–3 were reasonable. 
 
Compounds 1–3 were assayed for cytotoxicity and antimicrobial activity. When tested against 
the three cancer cell lines MCF-7, H460, and SF268 (Supporting Information Table S1), 
compounds 2 and 3 showed moderate cytotoxicity, while 1 was inactive. Compounds 2 and 3 
were equipotent against S. aureus, with MIC values of 25 μg/mL, while none of the compounds 
showed activity against C. albicans. 
 
 
Figure 3. Binding conformation of 1 (a), 2 (b), and 3 (c) predicted by Glide. Crystallographic 
rolipram (maroon) is shown as a reference with hydrogen bonds displayed as yellow/black 
dashes. Nonpolar hydrogen atoms are omitted. (d) Two-dimensional interaction map of the 
optimized docking model of compound 3 in the cAMP binding pocket of PDE4B. Amino acid 
residues within 4.5 Å of the ligand are displayed. Blue arrows indicate hydrogen bonding to 
amino acid side chain atoms. 
 
In conclusion, three compounds (1–3) were isolated and characterized from the fungus MSX 
47445. The structure of the new paraquinone, 3, was assigned unequivocally by NMR and 
single-crystal X-ray diffraction. The effect of compounds 1–3 on the activity of PDE4B was 
assessed both in vitro and in silico; compound 3 was the most potent, being approximately a 
half-order of magnitude less potent than the positive control, rolipram. Further studies are 
ongoing to expand the knowledge base of this class of compounds, particularly given their 
compact structures. 
 
Experimental Section 
 
General Experimental Procedures 
 
UV and IR spectra were acquired on a Varian Cary 100 Bio UV–vis spectrophotometer and a 
Perkin-Elmer Spectrum One with Universal ATR attachment, respectively. NMR experiments 
were conducted in either CDCl3, acetone-d6, or DMSO-d6 with TMS as a reference via a JEOL 
ECA-500, operating at 500 MHz for 1H and 125 MHz for 13C. HRESIMS was performed on a 
Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source. 
UPLC was carried out on a Waters Acquity system with data collected and analyzed using 
Empower software. HPLC was carried out using a Varian Prostar HPLC system equipped with 
ProStar 210 pumps and a Prostar 335 photodiode array detector, with data collected and analyzed 
using Galaxie Chromatography Workstation software (version 1.9.3.2). For preparative HPLC, a 
Phenomenex Synergi Max-RP 80 (4 μm; 250 × 21.2 mm) column was used at a 21 mL/min flow 
rate, while for the semipreparative HPLC, a Phenomenex Gemini-NX C18 (4 μm; 250 × 10 mm) 
column was used at a 4.7 mL/min flow rate. For UPLC, a Waters BEH C18 column (1.7 μm; 50 
× 2.1 mm) was used with a 0.6 mL/min flow rate. Flash chromatography was performed on a 
Teledyne ISCO CombiFlash Rf using a 40 g Silica Gold column and monitored by UV and 
evaporative light-scattering detectors. X-ray crystallography data were acquired using a Bruker 
APEX CCD diffractometer (Mo Kα̅ radiation, graphite monochromator). All other reagents and 
solvents were obtained from Fisher Scientific and were used without further purification. 
 
Producing Organism and Fermentation 
 
Mycosynthetix fungal strain 47445 was isolated from highly decomposed woody debris in 1990. 
The growth conditions were as described previously(9, 12) and outlined in the Supporting 
Information. For molecular identification, the internal transcribed spacer regions 1 and 2 and 
5.8S nrDNA (ITS) were sequenced, since this region of the rRNA operon has been proposed as a 
barcode marker for fungi.(36) Detailed methodology for DNA extraction, PCR amplification, 
sequencing, and phylogenetic analyses is outlined in the Supporting Information. The combined 
ITS and LSU sequence was deposited in GenBank (accession no. JX310275). The analyses of 
both the rRNA regions (ITS and D1/D2 of the LSU) suggested that MSX 47445 was a member 
of the Chaetothyriales, Ascomycota, and shares phylogenetic affinities with the mitosporic 
fungus Cyphellophora sp. 
 
Extraction and Isolation 
 
To the large-scale solid fermentation culture of MSX 47445 was added 500 mL of 1:1 MeOH–
CHCl3. The culture was chopped with a spatula and shaken overnight (∼16 h) at ∼100 rpm at rt. 
The sample was filtered with vacuum, and the remaining residues were washed with 100 mL of 
1:1 MeOH–CHCl3. To the filtrate were added 900 mL of CHCl3 and 1500 mL of H2O; the 
mixture was stirred for 2 h and then transferred into a separatory funnel. The bottom layer was 
drawn off and evaporated to dryness. The dried organic extract was reconstituted in 300 mL of 
1:1 MeOH–CH3CN and 200 mL of hexanes. The biphasic solution was stirred for an hour and 
then transferred to a separatory funnel. The MeOH–CH3CN layer was drawn off and evaporated 
to dryness under vacuum. The defatted material (1.2 g, orange-red) was dissolved in a mixture of 
CHCl3–MeOH, adsorbed onto Celite 545, and fractionated via flash chromatography using a 
gradient solvent system of hexane–CHCl3–MeOH at a 40 mL/min flow rate and 53.3 column 
volumes over 63.9 min to afford seven fractions. Fraction 2 eluted with 100% CHCl3 (∼247 mg) 
and was subjected to preparative HPLC using an isocratic system of 55:45 CH3CN–H2O over 30 
min at a flow rate of 4.7 mL/min to yield seven subfractions. Subfraction 5 yielded compound 1 
(30.2 mg), which eluted at ∼22.5 min. Subfraction 2 was subjected to semipreprative HPLC and 
yielded compounds 2 (12.1 mg) and 3 (6.2 mg), which eluted at 9.5 and 19.0 min, respectively. 
UPLC was used to evaluate the purity of 1–3 using a gradient solvent system that initiated with 
20:80 CH3CN–H2O to 100% CH3CN over 4.5 min; all compounds were >97% pure 
(Supporting Information Figure S1). 
Betulinan C (3): 
 
orange powder; UV (MeOH) λmax (log ε) 330 (3.62), 235 (4.14), 203 (4.32) nm; IR (diamond) 
νmax 1661, 1640, 1593, 1330, 1267, 1090, 1072, 935, 889, 849, 809, 776, 766 cm–1; 1H NMR 
(CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 1; HRESIMS m/z 291.1017 
[M + H]+ (calcd for C19H14O3 291.1016). 
 
X-ray Crystallography 
 
Crystallographic data for compound 3 have been deposited with the Cambridge Crystallographic 
Data Centre, deposition number 904704. Compound 3’s crystals were grown in ethyl acetate at 
rt. X-ray crystal structure analysis of 3 were as follows: formula C19H13O3, MW = 290.31, 
block-shaped yellow crystal, a = 14.6693(18) Å, b = 7.3806(9) Å, c = 14.3582(18) Å, β = 
115.259(1)°, T = 193(2) K, Z = 4, monoclinic, space group P2(1)/c, GOF = S = 1.043, V = 
1405.9(3) Å3, R1 (3088 reflections, I > 2σ(I)) = 0.0521, wR2 (all 3719 reflections) = 0.1476, λ = 
0.71073 Å. 
 
Cytotoxicity Assay 
 
The cytotoxicity measurements against the MCF-7(37) human breast carcinoma (Barbara A. 
Karmanos Cancer Center), NCI-H460(38) human large cell lung carcinoma (HTB-177, 
American Type Culture Collection (ATCC)), and SF-268(39) human astrocytoma (NCI 
Developmental Therapeutics Program) cell lines were performed as described previously.(40, 
41) 
 
Antimicrobial Assay 
 
The compounds were screened for antimicrobial activity using an agar plate diffusion assay as 
described previously.(8) 
 
Phosphodiesterase Inhibitor Assay 
 
The PDE inhibitor assay was performed at BPS Bioscience Inc. as described previously.(13) 
Detailed experimental procedures are provided in the Supporting Information. 
 
Molecular Modeling 
 
Compounds 1–3 were prepared using the LigPrep 2.4 module of Maestro 9.1 (Schrödinger, 
LLC). The crystal structure of human PDE4B in complex with the inhibitor rolipram was 
retrieved from the Protein Data Bank (PDB entry 1RO6).(42) Docking was performed with the 
cAMP catalytic domain using the Glide (Grid-Based Ligand Docking with Energetics; 
Schrödinger, LLC) program, version 5.6.(35) The Protein Preparation Wizard module of Maestro 
was used to prepare the protein.(43) During protein preparation, H2O molecules were deleted. 
For docking, the scoring grids were centered on the crystal structure of rolipram using the default 
bounding sizes. All structures were docked and scored using Glide.(35) The best docked poses 
were selected as the ones with the lowest Glide score; the more negative the Glide score, the 
more favorable the binding. 2D interaction maps were generated with Discovery Studio 3.1 from 
Accelrys Software Inc. 
 
Supporting Information 
 
Information about the producing organism and its fermentation, the experimental protocol for 
phosphodiesterase inhibitor assay, UPLC chromatograms of compounds 1–3, 1H and 13C NMR 
spectra for compound 3, two-dimensional interaction map of the optimized docking model of 
compounds 1, 2, and rolipram in the cAMP binding pocket of PDE4B, phylogram of the most 
likely tree, comparison between the binding position of rolipram within the crystal structure and 
the binding mode predicted by Glide, and cytotoxicity and antimicrobial activities of compounds 
1–3. This material is available free of charge via the Internet at http://pubs.acs.org. 
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